The Community Oncology Alliance (COA) responded to CMS' final Physician Fee Schedule Rule by commending the agency for listening and responding to feedback from stakeholders.
The Community Oncology Alliance (COA) responded to CMS' final Physician Fee Schedule Rule by commending the agency for listening and responding to feedback from stakeholders. COA praised CMS for the decision to not reduce payment for same day evaluation and management documentation and billing codes and the decision to to move toward site neutral payment parity.
However, COA did voice concern over cuts to reimbursement for the administration of chemotherapy, as well as a lower reimbursement for the introduction of new cancer drugs to wholesale acquisition price plus 1.35%. Read the full press release here.
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Oncology Practices Keep Pace With PBMs, in Court and Beyond
April 5th 2024This panel at the Community Oncology Alliance conference discussed the impact of pharmacy benefit manager (PBM) response to the end of direct and indirect remuneration fees, which has been dramatic cuts to cancer drug reimbursement.
Read More